PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.13%
Revenue growth of 18.13% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
126.49%
Gross profit growth of 126.49% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
7.01%
EBIT growth of 7.01% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
7.01%
Operating income growth exceeding 1.5x Healthcare median of 0.07%. Joel Greenblatt would see if unique processes drive exceptional profitability.
-223.94%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-151.50%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-151.50%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.66%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.66%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-1622.35%
Negative OCF growth while Healthcare median is -11.88%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-40695.39%
Negative FCF growth while Healthcare median is -9.55%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
591.73%
5Y CAGR of 591.73% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
590.91%
3Y CAGR of 590.91% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-9912.68%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-1199.97%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-255.95%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-2334.26%
Negative 10Y net income/share CAGR vs. Healthcare median of 1.29%. Seth Klarman might see a fundamental problem if peers maintain growth.
-938.00%
Negative 5Y CAGR while Healthcare median is 0.45%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-207.50%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
9571.99%
Equity/share CAGR exceeding 1.5x Healthcare median of 48.64% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
979.62%
5Y equity/share CAGR > 1.5x Healthcare median of 29.26%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
63.77%
3Y equity/share CAGR > 1.5x Healthcare median of 19.73%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.86%
AR growth of 10.86% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-1.92%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.65%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-2.43%
Negative BV/share change while Healthcare median is -5.36%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-6.92%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
119.27%
R&D growth of 119.27% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
34.23%
SG&A growth of 34.23% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.